Full Fed. Circ. Won't Revive Juno's $1.2B Cancer Patent Win
By Dani Kass (January 14, 2022, 7:34 PM EST) -- The full Federal Circuit said Friday that it will not review a panel decision wiping out Bristol-Myers Squibb subsidiary Juno Therapeutics' $1.2 billion patent infringement victory against Gilead's Kite Pharma Inc.
Juno, along with Memorial Sloan Kettering Cancer Center, had filed a petition in October urging either the original panel or full court to revive its massive trial win against Kite, but was entirely shot down without commentary. The panel had invalidated Sloan Kettering's patent, which Juno licenses, for its lack of written description.
The rehearing petition had claimed the panel used a "rigid, formalistic" test of the written description requirement, which...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!